Critical Care Research Group, Prince Charles Hospital, Brisbane, QLD, Australia.
Intensive Care Unit, Alfred Hospital, Melbourne, VIC, Australia.
Crit Care Resusc. 2017 Oct;19(Suppl 1):45-52.
Venovenous extracorporeal membrane oxygenation (VV ECMO) and extracorporeal CO2 removal (ECCO2R) are increasingly used in the management of severe respiratory failure. With bleeding complications being one of the major risks of these techniques, our aim in this systematic review was to assess the available literature on acquired von Willebrand syndrome (AvWS) and extracorporeal support. AvWS has previously been associated with bleeding and shear stress.
A systematic review, using Medline via PubMed, was performed to identify eligible studies up to January 2017.
The prevalence of AvWF among patients on VV ECMO or ECCO2R is high, but only a limited number of studies are reported in the literature. AvWS testing should be performed, including vWF multimer analysis, vWF activity and vWF antigen concentration. The extent to which vWF contributes to bleeding during ECMO, or how much changes in ECMO management can influence high molecular weight vWF multimer levels, cannot be answered from the currently available evidence and there remains a need for future studies.
静脉-静脉体外膜肺氧合(VV ECMO)和体外 CO2 去除(ECCO2R)越来越多地用于治疗严重呼吸衰竭。由于出血并发症是这些技术的主要风险之一,我们在这项系统评价中的目的是评估关于获得性血管性血友病综合征(AvWS)和体外支持的现有文献。AvWS 先前与出血和剪切应力有关。
通过 PubMed 对 Medline 进行了系统评价,以确定截至 2017 年 1 月的合格研究。
在接受 VV ECMO 或 ECCO2R 治疗的患者中,AvWF 的患病率很高,但文献中仅报道了有限数量的研究。应进行 AvWS 检测,包括 vWF 多聚体分析、vWF 活性和 vWF 抗原浓度。在 ECMO 过程中,vWF 对出血的贡献程度,或者 ECMO 管理的变化在多大程度上可以影响高分子量 vWF 多聚体水平,目前尚无证据可以回答,因此仍需要进一步研究。